A laboratory concentration–response plot records how a measured signal changes as peptide, ligand, or target concentration is varied under defined assay conditions. It is not a dosing chart. A slope, plateau, or midpoint such as an apparent Kd is only as informative as the observable on the y-axis, the span of concentrations actually tested, and the size of the fit error relative to the estimate. None of the abstracts below support converting buffer, serum, coating, or cell-culture concentrations into human doses.
The same word “response” does not imply the same curve
Binding fluorescence, covalent-adduct ratios, detector output, and cell endpoints are different observables. They do not share one Hill slope or one saturating plateau.
Zhang, Li, Li and colleagues (first publication date 11 June 2026) used proteolysis-resistant modified peptides from covalent ligand–acetylcholinesterase (AChE) adducts as a bidirectional laboratory indicator for ligand or enzyme. When AChE was adequate, the response ratio between modified and unmodified peptides (RM/U) correlated linearly with ligand concentration; when the given ligand was sufficient, RM/U correlated linearly with AChE content. Modified-peptide relative response (AM) against carbamate concentration instead followed sigmoid trajectories that agreed with a colorimetric Ellman assay, and that AM-versus-concentration curve enabled inhibition measurement of mixed pesticides. Linear versus sigmoid shape therefore depended on which partner was in excess and which peptide metric was plotted—not on a single universal dose–response model.
He, Sato and Nishizawa (14 September 2026) report a biochemical fluorescence titration, not a cellular efficacy study. Forced-intercalation Rev-peptide probes carrying thiazole orange at four substitution sites were tested against HIV RRE RNA. Probe E47 gave a 58-fold light-up and a bound-state fluorescence quantum yield (Φbound) of 0.31. Fluorescence titration afforded an apparent Kd of 0.84 ± 0.70 nM under the conditions employed. The fluorescence response to RRE was more than 2-fold that of tested non-cognate model RNAs, and E47 enabled concentration-dependent detection of an RRE RNA model with limits of detection of 190 pM in buffer and 220 pM in 10% serum.
Lee and co-workers (1 July 2026) blended silk fibroin-derived peptide into polycaprolactone at three discrete levels—0.2%, 0.5%, and 1% w/v—and measured surface and cell endpoints. Water contact angle fell from 78° on bare PCL to 62° at 1% peptide. Cell viability increased with peptide concentration, particularly at day 7, and CD31 expression was highest on the 1% substrates. Three composition points can show a trend in cell culture on coated materials; they do not define a Hill slope or prove that 1% is a maximum.
Sun and colleagues (3 September 2026) quantified free polyethylene glycol in three PEGylated peptide samples (PEG-loxenatide, pegmolesatide, and visepegenatide) by reverse-phase HPLC with charged aerosol detection. CAD response is inherently nonlinear; co-optimizing the power function value during acquisition and the power-law setting during processing linearized PEG concentration versus detector response. That linearized relationship is an analytical calibration for a process impurity, not a peptide’s biological dose–response.
Incomplete spans and large fit errors undercut midpoint claims
A midpoint is only as well determined as the baselines, the rising limb, and the upper plateau that surround it.
The E47 apparent Kd of 0.84 ± 0.70 nM is a concrete caution: the stated uncertainty is comparable to the point estimate, so the interval covers a large fraction of the nanomolar range under those conditions. The retrieved abstract does not report how many titration points were collected, the concentration span relative to Kd, whether both fluorescence asymptotes were reached, or which binding model was fitted. A limit of detection (190 pM in buffer; 220 pM in 10% serum) is also not an upper plateau. It is a lowest distinguished RNA concentration, not evidence that the light-up signal has saturated.
Zhang et al. show why missing saturating conditions change the story. Linear RM/U versus ligand required adequate AChE; linear RM/U versus AChE required sufficient ligand. Without those excess conditions, a truncated rising limb can be mistaken for a line, and mixed ligands may need the AM-versus-concentration format they used for pesticide mixtures. The abstract reports sigmoid agreement with the Ellman assay but does not give numerical IC50 values, slope factors, or the concentration window of those curves.
Lee et al. stop at 1% w/v peptide in the coating. Highest CD31 and improved viability at that level, in cell assays, do not establish a plateau; 1% may still lie on a rising limb. Those percentages describe blend composition in a biomaterials experiment, not a transferable potency.
As of 28 September 2026 (source capture date), a specific remaining question is unanswered in these abstracts: for the E47–RRE fluorescence titration, how many concentrations, over what span relative to 0.84 nM, and with which model produced an apparent Kd whose uncertainty (±0.70 nM) is almost as large as the estimate itself? Until those design details are available, the relative uncertainty is more informative than the central value.
What to check before quoting a slope or Kd
| Check | Why it matters | Illustration in these abstracts |
|---|---|---|
| What is on the y-axis? | Binding, adduct ratio, detector signal, and cell endpoints need different models | Fluorescence Kd; RM/U and AM; CAD; viability/CD31 |
| Were both plateaus observed? | Midpoints are poorly constrained without them | Three-point coating series; LOD is not saturation |
| Linear or sigmoid? | Linearity may hold only when one partner is in excess | RM/U linear with adequate AChE or sufficient ligand |
| Fit error versus estimate | Large relative error means the midpoint is weakly determined | Apparent Kd 0.84 ± 0.70 nM |
| Mixtures or matrix? | Curves can shift without a new mechanism | Mixed pesticides; 10% serum LOD |
| Assay class | Laboratory concentrations are not human doses | Buffer/serum RNA detection; AChE adducts; PCL cell culture; HPLC-CAD |
Explore Further
Browse our research peptide catalog and review third-party lab reports & COAs for published batches.
---
Research use only. The information above is provided for educational and laboratory research purposes only. The compounds discussed are not approved for human or veterinary use, diagnosis, treatment, or the prevention of any disease. Nothing here is medical advice.